Crescent Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crescent Biopharma (CBIO).

Price Target Range — 5 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$29Upside to Avg. PT+95.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Upgrade	Neutral→Buy	$36
Sep 14, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$27
Aug 27, 2026	Wedbush	Robert Driscoll	Maintained	Outperform	$27
Jun 1, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Downgrade	Buy→Neutral	—
Mar 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$25→$22
Jan 21, 2026	Guggenheim	Brad Canino	Initiate	Buy	$35
Aug 27, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Aug 25, 2025	Jefferies	Akash Tewari	Initiate	Buy	$26
Aug 11, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Initiate	Buy	$25
Jul 14, 2025	Wedbush	Robert Driscoll	Initiate	Outperform	$27
Jun 25, 2025	Stifel	Stephen Willey	Initiate	Buy	$28
Jun 18, 2025	LifeSci Capital	Charles Zhu	Initiate	Outperform	$22

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor upgrades Crescent Biopharma (NASDAQ:CBIO) from Neutral to Buy and announces $36 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.

Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Crescent Biopharma (NASDAQ:CBIO) from Buy to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.

Benzinga Newsdesk

Crescent Biopharma Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Crescent Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

People Also Watch

People Also Watch

Crescent Biopharma Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Crescent Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

PROWedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

PROWedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

PROHC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

PROHC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price Target

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22